Likewise, pretreatment (-60 min) with NGD 9002 (3, 10, and 30 mg/kg, og, n = 8 for each dose) reduced the icv CRF-stimulated FPO (5.9±1.5 vs iccv saline 0.3±0.3 number/60 min, p<0.05) to 3.9±0.7, 3.0±1.4 and 1.9±0.9 number/60 min respectively (p<0.05 at the highest dose, Fig. 3C) with an IC50 of 4.3 mg/kg. This evidence concerns the gene CRH and otopalatodigital syndrome type 2.